AVF4095g: A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal or Fallopian Tube Carcinoma

Trial Profile

AVF4095g: A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal or Fallopian Tube Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OCEANS
  • Sponsors Genentech
  • Most Recent Events

    • 05 Jun 2018 Results assessing cost-effectiveness of maintenance therapy from GOG 212,, GOG 218, ICON 7, OCEANS, GOG 213, NOVA, SOLO-2 ARIEL-3 and KEYNOTE-028 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 06 Dec 2016 Results published in the Genentech Media Release
    • 06 Dec 2016 According to a Genentech media release, based on the data from GOG-0213 and OCEANS trial the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top